Clinical Trial Update: First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC [Phase 2]

View source ↗

Summary

This Phase 2 trial of first-line atezolizumab, paclitaxel, and bevacizumab in metastatic triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Taxol (paclitaxel)
• Tecentriq (atezolizumab)

Snippet

Sponsor: MedSIR | Conditions: Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Status: COMPLETED